Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07556393Phase 2Completed

Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis

Role: lead

NCT06302426Phase 1Recruiting

Trial of INI-4001 in Patients With Advanced Solid Tumours

Role: lead

NCT06038279Phase 1Completed

Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.

Role: lead

All 3 trials loaded